Now showing items 1-2 of 2
Targeting FGFR to Overcome EMT-Related Resistance to EGFR Inhibition in EGFR-Mutated Non-Small Cell Lung Cancer
Acquired drug resistance to tyrosine kinase inhibitor (TKI) targeted therapies remains a major clinical challenge. In EGFR mutant non-small cell lung cancer (NSCLC), therapeutic failure of EGFR TKIs can result from both ...
Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants
The importance of oncogenic KRAS in human cancers have prompted intense efforts to target KRAS and its effectors. To anticipate the development of resistance to these strategies, we previously performed a genome-scale ...